Document is current

Article History

Received: 29 April 2023

Revised: 1 August 2023

Accepted: 9 August 2023

First Online: 23 October 2023

Declarations

:

: The scientific guarantor of this publication is Hanyu Jiang.

: All authors disclose no conflict of interest relevant to this work. Hanyu Jiang is a stock owner of Kanghong Technology Co., Ltd. Yuanan Wu is an employer of JD.com, Inc. Chengyu Ding is an employer of ShuKun (BeiJing) Technology Co., Ltd. Maxime Ronot received educational fees from Sirtex, Guerbet, Ipsen, Servier, GE Healthcare, Angiodynamics, and consulting fees (paid to the institution) from Quantum Surgical. Victoria Chernyak is a consultant for Bayer. Mustafa R. Bashir is the principal investigator on grants paid to his institution from the National Cancer Institute, Siemens Healthineers, NGM Biopharmaceuticals, Madrigal Pharmaceuticals, Carmot Therapeutics, and Corcept Therapeutics.

: Two of the authors (Yuanan Wu and Chengyu Ding) have significant statistical expertise.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained (West China Hospital (approval number, 2022–1993)).

: 262 patients included in the current study have been reported previously []. While the prior work proposed a non-hepatobiliary-specific MR alternative to HBP peritumoral hypointensity, the current work investigated the prognostic values, reliability, and clinical-radiological-pathological correlations for currently available MRI prognostic features.1. Jiang H, Wei H, Yang T, et al (2023) VICT2 trait: prognostic alternative to peritumoral HBP hypointensity in hepatocellular carcinoma. Radiology. 307(2):e221835.

: • Retrospective• diagnostic or prognostic study• performed at one institution